Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 4/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.41 |
| ▸ | HCN1 | O60741 | 1/20 | 0.40 |
| ▸ | F2R | P25116 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.38 |
| ▸ | PNLIP | P16233 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3238270 | 0.86 | ALDH1A1 (0.57) | ALDH1A1HPGDSLC6A9HCN1MEN1 | |
| SCHEMBL3238721 | 0.81 | ALDH1A1 (0.46) | ALDH1A1HPGDSLC6A9MEN1KMT2A | |
| SCHEMBL3237287 | 0.80 | SLC6A9 (0.45) | HPGDSLC6A9 | |
| SCHEMBL3236131 | 0.79 | ALDH1A1 (0.41) | ALDH1A1HPGDSLC6A9 | |
| SCHEMBL3243701 | 0.79 | CTSS (0.51) | SLC6A9MEN1KMT2A | |
| SCHEMBL3231206 | 0.79 | SLC6A9 (0.62) | SLC6A9 | |
| SCHEMBL3262723 | 0.79 | SLC6A9 (0.42) | SLC6A9KMT2A | |
| SCHEMBL3239594 | 0.79 | KCNQ3 (0.44) | ALDH1A1HPGDSLC6A9 | |
| SCHEMBL3240563 | 0.78 | KMT2A (0.49) | ALDH1A1HPGDSLC6A9MEN1KMT2A | |
| SCHEMBL3237670 | 0.78 | GAA (0.44) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | KCNK3 1960/4885KCNK9 1949/4885ALDH1A1 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.